Luciferase Reporter Cell Line - SK-BR-3

The SK-BR-3 cell line is a widely utilized human breast adenocarcinoma model, originally isolated in 1970 from a malignant pleural effusion of a patient with metastatic disease. Growing as an adherent epithelial monolayer, this line is clinically distinguished by the dramatic amplification and overexpression of the HER2/neu (ErbB2) receptor, alongside a lack of estrogen (ER) and progesterone (PR) receptor expression. Consequently, it serves as a classic foundational model for studying aggressive HER2-positive breast cancers. The Luciferase Reporter Cell Line - SK-BR-3 is an advanced derivative engineered through stable lentiviral transduction to constitutively express the firefly luciferase enzyme. This targeted genetic integration ensures that the modified cells continuously emit a robust, quantifiable bioluminescent signal upon exposure to the substrate D-luciferin. Crucially, this stable modification transforms the standard line into a highly sensitive cellular tracking tool while strictly preserving its original HER2-amplified phenotype, distinct receptor profile, and malignant characteristics.

Because it accurately represents HER2-driven malignancies, this reporter cell line is an invaluable resource for pre-clinical oncological research and targeted drug development. In vivo, the constitutive bioluminescent signal enables the non-invasive, longitudinal tracking of primary tumor growth and metastatic progression in xenograft mouse models. This allows researchers to dynamically monitor the spatiotemporal spread of the disease and precisely evaluate the in vivo efficacy of experimental treatments over time, significantly reducing the need for multiple endpoint sacrifices. In vitro, the robust bioluminescence facilitates rapid, high-throughput cell viability and cytotoxicity screening. Scientists rely on this quantifiable optical readout to evaluate the direct cytotoxic effects of novel chemotherapeutics, HER2-targeted monoclonal antibodies (such as trastuzumab), and innovative antibody-drug conjugates (ADCs), accelerating the discovery of precision therapies for aggressive breast carcinomas.